142 related articles for article (PubMed ID: 24326862)
1. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study.
Petrucci MT; Calabrese E; Levi A; Federico V; Ceccolini M; Rizzi R; Gozzetti A; Falco P; Lazzaro C; Martelli E; Boccadoro M; Lauria F; Liso V; Cavo M; Foa R
Tumori; 2013; 99(4):e193-202. PubMed ID: 24326862
[TBL] [Abstract][Full Text] [Related]
2. The cost of multiple myeloma and its complications: A single-center study from Oran, Algeria.
Haouatti F; Belhadj IK; Goumidi A; Yafour N; Toumi H
Ann Pharm Fr; 2024 Jun; 82(4):654-662. PubMed ID: 38340806
[TBL] [Abstract][Full Text] [Related]
3. Economic and clinical impact of multiple myeloma to managed care.
Cook R
J Manag Care Pharm; 2008 Sep; 14(7 Suppl):19-25. PubMed ID: 18774882
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.
Warren JL; Harlan LC; Stevens J; Little RF; Abel GA
J Clin Oncol; 2013 Jun; 31(16):1984-9. PubMed ID: 23569317
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Antunes L; Rocha-Gonçalves F; Chacim S; Lefèvre C; Pereira M; Pereira S; Zagorska A; Bento MJ
Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13026. PubMed ID: 30828907
[TBL] [Abstract][Full Text] [Related]
6. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
7. Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
LeBlanc R; Hollmann S; Tay J
J Popul Ther Clin Pharmacol; 2016; 23(1):e103-13. PubMed ID: 27337740
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Gonzalez-McQuire S; Yong K; Leleu H; Mennini FS; Flinois A; Gazzola C; Schoen P; Campioni M; DeCosta L; Fink L
J Med Econ; 2018 May; 21(5):450-467. PubMed ID: 29278014
[TBL] [Abstract][Full Text] [Related]
10. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
[TBL] [Abstract][Full Text] [Related]
11. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey.
Pierelli L; Berto P; Accorsi P; Milone G; Lopatriello S; Aiello A; Iacopino P; Olivieri A; Rambaldi A; Bosi A
Transfus Apher Sci; 2013 Dec; 49(3):615-22. PubMed ID: 23973731
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US.
Fonseca R; Hagiwara M; Panjabi S; Yucel E; Buchanan J; Delea T
Blood Cancer J; 2021 Feb; 11(2):35. PubMed ID: 33941766
[TBL] [Abstract][Full Text] [Related]
13. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
14. Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.
Touati M; Lamarsalle L; Moreau S; Vergnenègre F; Lefort S; Brillat C; Jeannet L; Lagarde A; Daulange A; Jaccard A; Vergnenègre A; Bordessoule D
Support Care Cancer; 2016 Dec; 24(12):5007-5014. PubMed ID: 27525991
[TBL] [Abstract][Full Text] [Related]
15. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
Marchesi F; Mengarelli A; Giannotti F; Tendas A; Anaclerico B; Porrini R; Picardi A; Cerchiara E; Dentamaro T; Chierichini A; Romeo A; Cudillo L; Montefusco E; Tirindelli MC; De Fabritiis P; Annino L; Petti MC; Monarca B; Arcese W; Avvisati G;
Transpl Infect Dis; 2014 Feb; 16(1):158-64. PubMed ID: 24215479
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
17. Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system.
Brøndum RF; Vestergaard AS; Børty L; Vesteghem C; Rytter AS; Nielsen MM; Severinsen MT; Jensen P; Gregersen H; El-Galaly TC; Dybkær K; Ehlers LH; Bøgsted M; Roug AS
Future Oncol; 2021 Sep; 17(25):3331-3341. PubMed ID: 34156281
[TBL] [Abstract][Full Text] [Related]
18. Cost analysis of a randomized stem cell mobilization study in multiple myeloma.
Varmavuo V; Silvennoinen R; Anttila P; Säily M; Sankelo M; Putkonen M; Ahonen J; Mahlamäki E; Mäntymaa P; Savolainen ER; Remes K; Jantunen E
Ann Hematol; 2016 Oct; 95(10):1653-9. PubMed ID: 27485453
[TBL] [Abstract][Full Text] [Related]
19. The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study.
Fattore G; Torbica A; Susi A; Giovanni A; Benelli G; Gozzo M; Toso V
BMC Neurol; 2012 Nov; 12():137. PubMed ID: 23150894
[TBL] [Abstract][Full Text] [Related]
20. Healthcare costs of multiple myeloma: an Italian study.
Koleva D; Cortelazzo S; Toldo C; Garattini L
Eur J Cancer Care (Engl); 2011 May; 20(3):330-6. PubMed ID: 20148933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
